What are the side effects of taking resmetirom?

Resmetirom-Rezdiffra, as a new liver-targeted drug, has generally good safety, but it may still cause certain side effects, which requires the attention of clinicians and patients. The most common side effects include gastrointestinal effects such as mild nausea, diarrhea, abdominal pain, or indigestion. These symptoms are usually mild, can be tolerated by most patients, and tend to resolve with prolonged medication.

In addition, some patients may experience changes in their blood lipid profiles, such as fluctuations in low-density lipoprotein (LDL) levels and mild decreases in triglycerides. This is related to the mechanism of action of the drug in regulating hepatic lipid metabolism and can usually be controlled safely with monitoring. Since resmetirolacts through thyroidβ receptors, a small number of patients may experience slight heart rate changes or fluctuations in thyroid function indicators. However, these situations are rare and require regular monitoring under the guidance of a doctor.

It should be noted that for patients with decompensated cirrhosis, the liver function is severely impaired, the drug metabolism ability is reduced, and the risk of side effects is significantly increased. Therefore, this group is not suitable for the use of resmetirol. In addition, long-term safety data are still accumulating. For elderly patients or patients with multiple diseases, liver and kidney function, blood lipid indicators, and cardiovascular status should be carefully evaluated.

Generally speaking, the side effects of resmetirol are controllable, and most of them are mild to moderate, and can be managed by adjusting the dose, taking it in divided doses, and regularly monitoring it. Compared with its potential benefits in improving liver fat, fibrosis and lipid metabolism, the risk of side effects is relatively low. This is why international guidelines consider rismetirol as one of the potential priority treatment options for patients with non-cirrhotic NASH. . In the future, with the accumulation of clinical experience and the advancement of local approval, resmetirol is expected to become an important treatment option for domestic NASH patients and fill the current gap in drug treatment.

Reference materials:https://www.drugs.com/monograph/resmetirom.html